Introduction
The transplantation of autologous hematopoietic grafts constitutes a good therapeutic option for the treatment of leukemia patients in those cases in which no histocompatible donors are found. 1, 2 One of the concerns of the autologous transplantation of these grafts derives from the possibility of their contamination with leukemia cells, which will be then infused into the patient at the time of the hematopoietic transplantation. This was confirmed by the gene marking studies of MK Brenner et al. 3 in acute myeloid leukemia (AML) patients, who demonstrated the contribution of transplanted leukemia cells in relapsed patients. Similar observations were reported later in chronic myeloid leukemia 4 and neuroblastoma 5 patients, who received autologous hematopoietic grafts, suggesting the frequency of such a risk in this transplantation modality. Pharmacologic and immunologic approaches aiming at the elimination of the leukemia cells from hematopoietic autografts have been frequently used in the past. 6, 7 However, problems of toxicity on the healthy hematopoietic progenitor and stem cells have limited the use of these approaches in the clinics. 8, 9 More recently, positive or negative cell selection approaches have been used as a procedure to reduce the tumor burden in the graft. 10, 11 This constituted a safe approach for those cases in which the cancer cells display differential membrane antigens compared to the healthy hematopoietic progenitors and stem cells, 12, 13 something that is not generally the case in myeloid leukemias. 14 With the purpose of improving the efficacy of cell purging procedures in hematopoietic autografts, new approaches aiming at the specific transfer of suicide genes into neoplasic cells have been recently proposed. On the basis of the high tropism of adenoviruses for epithelial cells, and because of the more limited efficacy of these vectors for transducing hematopoietic progenitors and stem cells, approaches based on the use of suicide adenoviral vectors have been proposed for the purging of hematopoietic grafts contaminated with carcinoma cells. [15] [16] [17] [18] [19] In a mouse model we have previously shown that 100% of the myelomonocytic WEHI-3B leukemia cells can be transduced under conditions that only transduced 20-30% of normal bone marrow (BM) cells, including the primitive population of Lin À Sca + progenitors. 20 In the current study, we have mimicked the relapse of patients infused with leukemiacontaminated autografts to show the efficacy of suicide adenoviral vectors in autograft purging strategies.
Results
Experimental conditions for inducing a selective cytotoxicity on leukemia versus normal BM cells with suicide adenoviral vectors
In order to facilitate the purging of leukemia-contaminated grafts, we used recombinant adenoviral vectors encoding the cytosine deaminase gene (AdCD), which transform the prodrug 5-fluorocytosine (5-FC) into the cytotoxic molecule, 5-fluorouracil (5-FU). To demonstrate the safety of 5-FC and the efficacy of 5-FU for the purging of leukemia-contaminated grafts, increasing concentrations of both drugs were added to mouse BM and leukemia WEHI-3B cultures. As shown in Figure 1 , 5-FC induced a modest toxicity in WEHI-3B cells, being the IC 50 dose 250 mM. In normal BM, 5-FC was even less toxic, since doses as high as 500 mM were compatible with CFC survivals of 60%. In contrast to these observations, the active product 5-FU was highly toxic to both cell types. A very low dose of 5 nM of 5-FU completely inhibited the clonogenic potential of BM and WEHI-3B cells ( Figure 1 ). These data indicated the efficacy of the pharmacological system selected for the purging strategy and indicated the necessity of selectively transducing the leukemia cells with the adenoviral vector to confer a safe suicide purging method. Aiming to eradicate the growth of WEHI-3B cells without affecting the functionality of normal BM grafts, transduction conditions similar to those previously described with adenoviral-vectors encoding the b-galactosidase or the EGFP marker genes were used. We previously showed that under the described experimental conditions of infection (2-8 h of incubation with 100 PFU AdCD/cell), 100% of leukemic cells can be transduced and the expression of the transgene maintained for more than 4 days. 20 After infection, clonogenic assays were conducted in the presence and the absence of 75 mM 5-FC. As shown in Figure 2 , no cytotoxicity was observed in cultures of WEHI-3B cells that had been transduced with the AdCD, or alternatively incubated with 5-FC. However, WEHI-3B samples that were both transduced with the AdCD vector and incubated with 5-FC were incapable of generating colonies in vitro.
To investigate whether these conditions induced a significant toxicity in the clonogenic potential of normal BM, the highest infection period used for transducing WEHI-3B cells (8 h ) and up to 300 PFU of AdCD/cell were used to transduce these samples. Clonogenic assays were then conducted with and without 75 mM 5-FC. A nonsignificant decrease in the number of colonies was observed as a result of the transduction and treatment with 5-FC, which never exceeded a 20% reduction of values corresponding to mock-transduced samples multiplicity of infection (multiplicity of infection (moi)¼0; Figure 3 ).
Leukemia purging efficacy of suicide adenoviral vectors in a model mimicking the relapse of recipients transplanted with leukemia-contaminated autografts Aiming to demonstrate the efficacy of the adenoviral purging strategy, a transplantation model that mimicked the relapse of patients owing to the infusion of leukemiacontaminated autografts was used. 21 Myeloablated recipients were transplanted with 2 Â 10 6 BM cells contaminated with 10 5 syngenic WEHI-3B cells, either parental or genetically marked with a provirus encoding Purging of leukemia-contaminated bone marrow grafts J Garcia-Castro et al the neo r and NGFR genes (see Materials and methods). These conditions reproduce a human transplantation involving the infusion of 4 Â 10 7 BM cells/kg weight bearing a contamination of 5% leukemia cells. In each experiment, two aliquots of this cell suspension were respectively subjected to mock transduction or to transduction with the AdCD (4 h; 100 PFU/cell) and then transplanted. From each of these two groups, half of the animals were treated with saline and half with 5-FC, as indicated in Materials and methods.
As shown in Figure 4 , every recipient that had been transplanted with mock-transduced samples, regardless of the administration of 5-FC, died within a period of 50 days post-transplantation. From the group that had been transplanted with AdCD-transduced samples, 90% of mice that were treated with saline died during the same period. However, the administration of 5-FC to recipients transplanted with the same graft resulted in a 90% survival in the long term (see Figure 4) .
To investigate the cause of death of transplanted animals, moribund mice were killed and signs of leukemia disease were evaluated. Each of the analyzed recipients that was not subjected to the complete purging process (AdCD transduction plus 5-FC treatment) showed the characteristic splenomegalia (see Figure 5a ) and hepatomegalia (not shown) of mice developing myeloid leukemia. This was not the case in mice corresponding to the purged group when killed at the end of the experiment (9 months post-transplantation), nor in the only mouse that became moribund at 40 days post-transplantation. Purging of leukemia-contaminated bone marrow grafts J Garcia-Castro et al
To confirm that no leukemia cells were present in recipients transplanted with purged grafts, WEHI-3B cells genetically marked with a neo r /NGFR provirus were used in some experiments (see Materials and methods). As shown in Figure 5b , either the liver, the BM or the spleen of mice transplanted with unpurged BM contained a significant population of leukemia cells, recognized by the expression of the NGFR marker. In contrast to this observation, no evidence of NGFR + cells was observed in mice transplanted with the purged BM (Figure 5b ). These conclusions were confirmed by polymerase chain reaction (PCR) analysis of the neo r sequence, also present in this clone of WEHI-3B cells. As shown in Figure 5c , liver and BM samples from all experimental groups, except that corresponding to mice transplanted with the purged BM, showed a clear band corresponding to the neo r sequence. With the final purpose of investigating the functionality of the hematopoiesis of animals transplanted with purged samples, the presence of donor hematopoiesis was first investigated in these recipients, as well as in recipients transplanted with unpurged grafts. Male mice were always chosen as BM donors, with the aim that only the DNA from these animals -but not from recipient females nor from WEHI-3B cells -could hybridize with the male PY2 probe. As deduced from the dot-blot analysis of BM-derived DNA (see representative analysis in Figure 6a ), a predominant donor repopulation was observed in recipients transplanted with unpurged samples at the time they became moribund (around 30-50 days post-transplantation). Significantly, when recipients transplanted with the purged samples were killed at 9 months post-transplantation, also a predominant donor repopulation was observed ( Figure 6 ). Similar observations were obtained in secondary recipients transplanted with 10 7 BM cells from these latter animals (analysis was made at 4 months post-transplantation; Figure 6 , lower panel), consistent with the long-term repopulating capacity of the purged graft.
As a further control of the functionality of purged grafts, hematological and hematopoietic analyses of primary recipients were also made at 9 months posttransplantation, and compared to data obtained in recipients that had been subjected to conventional transplantation with 2 Â 10 6 uncontaminated BM cells. Purging of leukemia-contaminated bone marrow grafts J Garcia-Castro et al
No differences in the PB counts were observed between groups transplanted with both graft types (not shown). Also, no significant differences in the number of myeloid and megakaryocytic progenitors were detected between groups transplanted with conventional and purged samples (Figure 7) , showing that the purging process did not significantly affect the functionality of donor hematopoiesis in recipient mice. This final result indicates that the suicide gene transfer approach proposed in this study for the purging of leukaemia cells not only represents an efficient approach in this experimental transplantation model, but also constitutes a safe procedure for preserving the functionality of the hematopoietic graft.
Discussion
Recent gene-marking studies have shown that tumor cells contaminating autologous hematopoietic grafts may contribute to the leukemia relapse of transplanted patients, [3] [4] [5] indicating the convenience of efficiently purging grafts used for autotransplants. Several reports have shown modest, although significant improvements in the post-transplantation leukemia-free survival in patients who received purged grafts. [22] [23] [24] However, the benefits associated with current purging procedures are under discussion mainly because of problems of engraftment and stem cell toxicity. 25, 26 Aiming to improve current procedures of leukemia purging, approaches based on the use of vectors capable of selectively transducing leukemia cells with suicide genes have been proposed. [15] [16] [17] [18] Our study aiming at the BM purging with suicide adenoviral vectors, shows 90% of disease-free survival in myeloablated mice transplanted with a leukemia-contaminated graft. To the best of our knowledge, this study constitutes the first in vivo demonstration of the efficacy of suicide adenoviral vectors for the purging of hematopoietic grafts contaminated with myeloid leukemia cells.
The suicide system used in this study is based on the selective transfer of cytosine deaminase (CD) gene to the cancer cells. 27, 28 This enzyme deaminates the relatively nontoxic 5-FC, generating a highly toxic drug, 5-FU. Both 5-FC and 5-FU have been extensively used in the clinics in the treatment of infections 29 and chemotherapy of neoplasias, 30 respectively. As shown in Figure 1 , our data clearly demonstrate that the prodrug 5-FC has a very low toxicity in the normal and leukemic cells, while the 5-FU prodrug is highly toxic for both cell populations ( Figure  1 ).
For the optimal design of a purging protocol with viral vectors, two main topics need to be addressed: the specific targeting of the suicide adenoviral vectors for the leukemic cells and the preservation of the hematopoietic functionality of the graft during the purging process.
Several groups, including ours, have demonstrated an efficient adenoviral transduction of different leukemic cell lines (WEHI-3B, Jurkat, U937, K562, SAS413). 20, [31] [32] [33] These experiments demonstrate that, although heterogenous, leukemic cells are susceptible to adenoviral vectors. Few reports have studied the transduction efficacy of first-generation adenoviral vectors in primary AML cells, and the results obtained were largely variable, mainly because of differences in the experimental conditions used for transduction. [34] [35] [36] [37] Higher percentages of AML transduction have been obtained using tropism-modified or alternative serotypes adenovirus. [38] [39] [40] However, these vectors also transduced more efficiently the normal hematopoietic progenitors. 41, 42 In some instances, the expression of the coxsackievirus and adenovirus receptor (CAR) and the expression of the avb3/5 integrins -which act as coreceptors for adenoviral infections -have been studied in adenovirussusceptible cells. 20, 29 In this respect, we have reported that the expression of CAR receptor and integrin coreceptors is significantly higher in WEHI-3B than in normal BM cells. 20 This observation could explain the differential susceptibility of both cell types to adenoviral vectors, and suggest that the expression of these receptors could be used as indicative of the susceptibility of primary leukemias to adenoviral vectors.
Using first-generation adenoviral vectors, we showed the possibility of transducing 100% of myelomonocytic ) from recipients of purged samples were transplanted into secondary female recipients and the male chimerism was analyzed at 120 days posttransplantation. Control samples were performed by mixing DNA from male and female in the percentages showed (100%, only male DNA; 0%, only female DNA). Figure 7 Clonogenic potential of BM samples of purged recipients. Analysis of myeloid and megakaryocytic progenitors at 270 days posttransplantation from recipients transplanted with leukemia-contaminated grafts subjected to the adenoviral-mediated purging process (dark bars) compared to samples harvested from recipients receiving conventional transplants of normal BM (white bars). Bars represent the mean7s.e. of data corresponding to four mice from each group.
Purging of leukemia-contaminated bone marrow grafts J Garcia- (Figures 2 and 3) . Moreover, using a leukemia-relapse model previously developed in our laboratory, 21 we now show the efficacy of this approach for eradicating the leukemia repopulating cells, which contaminate mouse BM grafts. In particular, here we demonstrate that leukemia-contaminated grafts whose transplantation results in the leukemia dissemination -and thus the death of all transplanted recipientscan be efficiently purged so that 90% of recipients survive in the long term (Figure 4) . Moreover, as deduced by the histological examination of the recipient's tissues and by conducting FACS and PCR analyses of genetic markers previously inserted into the leukemic cells, our observations show that none of the BM purged recipients evidenced any sign of leukemia disease.
On the basis of previous studies showing the ability of adenoviral vectors for transducing normal hematopoietic progenitors, 43, 44 a concern related to the repopulating potential of purged grafts could be deduced. Nevertheless, a relatively high efficient transduction of hematopoietic progenitor cells with adenoviral vectors has been currently associated with the use of very long periods of infection in the presence of growth factors and/or very high multiplicities of infection. Our conditions of serum-and cytokine-free infections gave us a minimal transduction, 20 and thus a nonsignificant inhibition of normal hematopoietic progenitors as a result of the suicide purging approach presented in this study. Moreover, using an in vivo transplantation model, we show very high levels of exogenous repopulation not only in the short term, but also in the long-term posttransplantation, as well as in secondary recipients ( Figure 6 ). Although the sensitivity of the dot-blot analyses may not detect small changes in the repopulating ability of the BM samples, the repopulating and clonogenic results shown in Figures 6 and 7 indicate that the purging process used to eradicate the leukemic cells did not compromise the hematopoietic functionality of the BM grafts. Our data, therefore, offers direct evidence showing the compatibility of the proposed purging approach with the preservation of the hematopoietic stem cells from purged grafts.
A number of groups, including ours, have previously shown the efficacy of suicide adenoviral vectors for the purging of hematopoietic grafts contaminated with carcinoma cells. [15] [16] [17] [18] [19] The current study, however, offers the first in vivo demonstration of the efficacy of these approaches for the purging of grafts contaminated with leukemic cells. Taken together, we propose that purging approaches based on the transduction of leukemia cells with suicide adenoviral vectors could be efficiently used for eradicating leukemia cells that contaminate hematopoietic autografts. Further studies with human leukemia cells are in progress aiming to define which of the different human leukemia cell types would be particularly susceptible for adenovirus transduction and, therefore, suitable for conducting adenoviral-mediated gene purging protocols.
Materials and methods

Animals
Balb/c ByJ mice (10-12 weeks old) were used throughout. Breeding pairs were originally obtained from Jackson Laboratory (Bar Harbor, ME, USA) and bred at the CIEMAT Animal Facility (Registration number 28079-21A). Mice were maintained under high standard conditions (HEPA filtered air, regulated temperature of 221C, light/dark cycle of 12 h, and allowed food and UVirradiated water ad libitum) and routinely screened for pathogens, in accordance with the Federation of European Laboratory Animal Science Associations (FELA-SA) procedures. All the experiments were conducted according to the Spanish regulation (RD 951/1997 of Ministerio de Presidencia and RD 233/1988 of Ministerio de Agricultura, Pesca y Alimentació n) about the use and treatment of experimental animals.
Cultures of leukemia and normal BM cells
WEHI-3B D
+ leukemia cells (Balb/c genetic background) were obtained from ECACC (Salisbury, UK) and maintained in suspension cultures with RPMI 1640 medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS; Gibco), L-glutamine (2 mM; Gibco) and antibiotics (penicillin 100 U/ml and streptomycin 50 mg/ml; Gibco). In experiments where WEHI-3B cells were grown in semisolid media, cell suspensions were mixed with Bactoagar (0.3% final concentration, Difco Laboratories, Detroit, MI, USA), seeded in 35-mm plastic culture dishes (Nunc, Roskilde, Denmark), cultured for 7 days and stained with (2-p-iodophenyl)-3-(pnitrophenyl)-5-phenyl tetrazolium chloride (INT, Janssen Chemica, Beerse, Belgium). To facilitate the identification of the leukemia cells in transplanted recipients, a clone of WEHI-3B cells which both expressed the phosphotransferase resistant gene (neo r ) and the low-affinity human nerve growth factor receptor (NGFR; WEHI-3B/NGFR-8 clone) was used in some experiments. Previous studies showed similar in vitro and in vivo properties of this clone compared to the parental cell line. 21 BM cells obtained from femora and tibiae of Balb/c mice were resuspended in Iscove's modified Dulbecco's medium (IMDM; Gibco). The cellular suspension was passed through a 25-gauge needle, and the total number of nucleated cells was determined with a hemocytometer. For the culture of CFU-GM progenitors, BM cells were plated in MethoCult GF M3534 culture media (StemCell Technologies, Vancouver, BC, Canada) at a concentration of 10 5 cells/plate and cultured for 7 days. For the culture of CFU-Meg progenitors 10 5 cells were seeded in plates containing the MegaCult C medium (StemCell Technologies). Megakaryocitic colonies were recognized by the acetylcholinesterase staining. 45 All cultures were grown at 371C, in a 95% humidified atmosphere with 5% CO 2 .
Transduction with adenoviral vectors
Serotype 5 adenovirus-derived vectors were prepared and titrated as previously described. 18 The adenoviral vector AdCD expresses the CD gene under the control of the CMV promoter, which has been introduced in the E1 region of the adenovirus. Cells were infected with the AdCD vector at different moi and infection times in IMDM medium, without serum and in the presence of 8 mg/ml polybrene. After infection, cells were washed and resuspended in fresh media.
In vivo studies
Transplantation studies were conducted according to an experimental model that mimics the relapse of recipients infused with leukemia-contaminated autografts. 21 Briefly, samples containing normal BM cells from male Balb/c mice were contaminated with 5% of syngenic WEHI-3B or WEHI-3B/NGFR-8 cells. Aliquots of 0.2 ml containing 2 Â 10 6 BM cells and 10 5 leukemia cells were i.v. injected into female Balb/c recipients (10-12 animals per group), which had been previously conditioned with an aplastic regimen consisting of two doses of 4.5 Gy spaced 4 h apart (Philips MG324 X-ray equipment, at 300 kV, 10 mA; dose rate: 1.03 Gy/min). In the leukemia purging experiments, mice were treated from day 0 to day 4 with the procytotoxic drug 5-FC (Roche Pharma, Switzerland; two i.p. doses of 10 mg 5-FC per day). Mice were killed when moribund or at the end of the experiment, and tissues were obtained for evaluation of tumor infiltration and hematopoietic functionality. For secondary transplant, 1 Â 10 7 BM cells from primary recipients of purged samples were injected i.v. into secondary female Balb/c recipients that were conditioned as described above.
FACS analysis
For detecting the presence of NGFR-marked leukemia cells in the tissues of recipient mice, dispersed cells were washed in PBA (phosphate-buffered saline containing 0.1% (w/v) bovine serum albumin and 0.02% (w/v) sodium azide), incubated at 41C for 30 min with 50 ml of titrated FITC-conjugated mouse anti-NGFR monoclonal antibody (Boehringer Mannheim, Germany) and washed again. To exclude dead cells, propidium iodide (1 mg/ml) was added to the samples before analysis. Cells were analyzed in a Coulter EPICS XL apparatus. Typically 10 000 viable cells were collected. Offline analysis was done by using the WinMDI free software package (a kind gift of Dr J Trotter, The Scripps Research Institute, La Jolla, CA, USA).
PCR
PCR reactions were carried out in a final volume of 50 ml with 0.25 mg DNA, 0.4 mM each primer, 0.5 Taq DNA polymerase (Boehringer Mannheim), 0.2 mM PCR Nucleotide Mix (Boehringer Mannheim), 10 mM Tris pH 8.3, 50 mM KCl and 1.5 mM MgCl 2 . The reaction profile consisted of 35 cycles for 30 s at 941C, 30 s at 571C and 1 min at 721C with a final elongation period of 10 min at 721C linked to a 101C bath. PCR reactions were electrophoresed in 1.5% agarose gels and visualized under ultraviolet light after ethidium bromide staining. The 642 bp neo r gene fragment present in the LNSN provirus was amplified by using primers GGAGAGGC-TATTCGGCTATG as sense strand and GCCAACGC-TATGTCCTGATA as antisense strand.
Analysis of the hematopoietic chimerism of transplanted recipients
To determine the level of hematopoietic chimerism of transplanted recipients, DNA was extracted from femoral BM and hybridized with the pY2 probe recognizing a male-specific sequence (donor origin), as previously shown. 46 Briefly, 1 mg of purified genomic DNA was denatured, adjusted to 1 M ammonium acetate and applied under a low vacuum onto nitrocellulose membranes (Schleicher and Schuell, Dassel, Germany) in a dot-blot set. Membranes were washed twice with 1 M ammonium acetate, dried at 371C and baked for 2 h at 801C. The fixed membranes were prehybridized for 3 h at 501C in 10 mM Tris pH 7.5, 50% formamide, 5 Â SSC, 5 Â Denhardt's reagent, 0.5% SDS and 50 mg/ml carrier DNA, and then hybridized overnight with 10% dextransulfate and hybridized with an EcoRI/SalI fragment of the pY2 plasmid (kindly provided by Dr E Palmer, National Jewish Hospital, Denver, CO, USA) labelled with a-32 P-dCTP by random priming. Membranes were washed three times, once every hour, at 561C in 0.1 Â SSC and 0.5% SDS, once in 2 Â SSC and exposed wet.
